Your browser doesn't support javascript.
loading
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Chataway, Jeremy; De Angelis, Floriana; Connick, Peter; Parker, Richard A; Plantone, Domenico; Doshi, Anisha; John, Nevin; Stutters, Jonathan; MacManus, David; Prados Carrasco, Ferran; Barkhof, Frederik; Ourselin, Sebastien; Braisher, Marie; Ross, Moira; Cranswick, Gina; Pavitt, Sue H; Giovannoni, Gavin; Gandini Wheeler-Kingshott, Claudia Angela; Hawkins, Clive; Sharrack, Basil; Bastow, Roger; Weir, Christopher J; Stallard, Nigel; Chandran, Siddharthan.
Afiliação
  • Chataway J; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London (UCL) Queen Square Institute of Neurology, Faculty of Brain Sciences, UCL, London, UK; National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, U
  • De Angelis F; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London (UCL) Queen Square Institute of Neurology, Faculty of Brain Sciences, UCL, London, UK.
  • Connick P; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
  • Parker RA; Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.
  • Plantone D; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London (UCL) Queen Square Institute of Neurology, Faculty of Brain Sciences, UCL, London, UK.
  • Doshi A; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London (UCL) Queen Square Institute of Neurology, Faculty of Brain Sciences, UCL, London, UK.
  • John N; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London (UCL) Queen Square Institute of Neurology, Faculty of Brain Sciences, UCL, London, UK.
  • Stutters J; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London (UCL) Queen Square Institute of Neurology, Faculty of Brain Sciences, UCL, London, UK.
  • MacManus D; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London (UCL) Queen Square Institute of Neurology, Faculty of Brain Sciences, UCL, London, UK.
  • Prados Carrasco F; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London (UCL) Queen Square Institute of Neurology, Faculty of Brain Sciences, UCL, London, UK; Department of Medical Physics and Biomedical Engineering, Centre for Medical Image Computing, UCL, London, UK; Uni
  • Barkhof F; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London (UCL) Queen Square Institute of Neurology, Faculty of Brain Sciences, UCL, London, UK; Department of Medical Physics and Biomedical Engineering, Centre for Medical Image Computing, UCL, London, UK; Dep
  • Ourselin S; School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK.
  • Braisher M; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London (UCL) Queen Square Institute of Neurology, Faculty of Brain Sciences, UCL, London, UK.
  • Ross M; Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.
  • Cranswick G; Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.
  • Pavitt SH; Dental Translational and Clinical Research Unit, University of Leeds, Leeds, UK.
  • Giovannoni G; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, UK.
  • Gandini Wheeler-Kingshott CA; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London (UCL) Queen Square Institute of Neurology, Faculty of Brain Sciences, UCL, London, UK; Brain MRI 3T Research Center, IRCCS Mondino Foundation, Pavia, Italy; National Institute for Health Research, Univ
  • Hawkins C; Keele Medical School and Institute for Science and Technology in Medicine, Keele University, Keele, UK.
  • Sharrack B; Department of Neuroscience, Royal Hallamshire Hospital, Sheffield, UK.
  • Bastow R; Patient Representative, Multiple Sclerosis Society, London, UK.
  • Weir CJ; Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.
  • Stallard N; Statistics and Epidemiology, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK.
  • Chandran S; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
Lancet Neurol ; 19(3): 214-225, 2020 03.
Article em En | MEDLINE | ID: mdl-31981516
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fármacos Neuroprotetores / Esclerose Múltipla Crônica Progressiva Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fármacos Neuroprotetores / Esclerose Múltipla Crônica Progressiva Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article